LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE Drug Patent Profile

« Back to Dashboard

When do Lamivudine, Nevirapine And Zidovudine patents expire, and when can generic versions of Lamivudine, Nevirapine And Zidovudine launch?

Lamivudine, Nevirapine And Zidovudine is a drug marketed by Micro Labs and is included in one NDA.

The generic ingredient in LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE is lamivudine; nevirapine; zidovudine. There is one drug master file entry for this compound. Additional details are available on the lamivudine; nevirapine; zidovudine profile page.

Summary for LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	45
DailyMed Link:	LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE at DailyMed

Recent Clinical Trials for LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Johns Hopkins University	Phase 1/Phase 2
The Aurum Institute NPC	Phase 1/Phase 2
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)	Phase 4

See all LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE clinical trials

US Patents and Regulatory Information for LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Micro Labs	LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE	lamivudine; nevirapine; zidovudine	TABLET;ORAL	205626-001	Aug 13, 2018		DISCN	Yes	No

Lamivudine, Nevirapine and Zidovudine: Market Dynamics, Patent Position and Financial Trajectory

Last updated: October 16, 2026

The lamivudine-nevirapine-zidovudine combination is a mature, generic antiretroviral regimen with limited commercial growth potential. Its market has shifted from branded sales in high-income countries to donor-funded procurement, public-health programs and low-cost generic supply in lower- and middle-income countries. The combination has no significant remaining composition-of-matter patent barrier in major markets, and its clinical use has declined as integrase inhibitor regimens replaced nevirapine- and zidovudine-based therapy.

Product-level revenue is generally not reported because the three active ingredients are sold separately, in multiple fixed-dose combinations, and through government tenders. The financial trajectory is therefore best assessed through treatment guidelines, procurement volumes, generic pricing and competitive substitution rather than branded sales.

What is the lamivudine-nevirapine-zidovudine combination?

Lamivudine, nevirapine and zidovudine are nucleoside or non-nucleoside reverse transcriptase inhibitors used in combination to suppress HIV replication.

Ingredient	Class	Common historical role	Current market position
Lamivudine	NRTI	Backbone agent in two- and three-drug regimens	Still widely used, often with dolutegravir
Zidovudine	NRTI	Early backbone agent and prevention-of-mother-to-child-transmission therapy	Reduced use because of toxicity and pill burden
Nevirapine	NNRTI	Low-cost third agent in first-line therapy	Largely displaced by dolutegravir and other newer agents

The combination is commonly described as an NVP/ZDV/3TC regimen. Generic products have included fixed-dose tablets marketed by manufacturers such as Cipla and other suppliers serving international procurement markets. The exact product name, strength, registration status and availability vary by country.

The regimen should not be confused with Combivir, which contains lamivudine and zidovudine but does not contain nevirapine. Combivir was developed and commercialized by Glaxo Wellcome and later GSK.

What is the FDA regulatory status of lamivudine, nevirapine and zidovudine?

The FDA approved the individual active ingredients during the early development of combination antiretroviral therapy:

Drug	Original U.S. product	Original sponsor	Regulatory history
Zidovudine	Retrovir	Burroughs Wellcome	First approved in 1987
Lamivudine	Epivir	Glaxo Wellcome	Approved in 1995
Nevirapine	Viramune	Boehringer Ingelheim	Approved in 1996
Lamivudine/zidovudine	Combivir	Glaxo Wellcome	Approved in 1997

The FDA Orange Book lists approved products and patent information for approved applications, but it does not establish a major U.S. commercial market for a single lamivudine-nevirapine-zidovudine product. The three-drug fixed-dose combination has not become a major U.S. branded product.

FDA treatment guidance has moved toward integrase strand transfer inhibitor regimens, particularly dolutegravir- or bictegravir-based therapy. Nevirapine is not a preferred modern first-line agent in U.S. treatment guidelines because of resistance, drug interactions and adverse-event considerations (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2024).

What patents protect lamivudine, nevirapine and zidovudine?

The principal composition-of-matter patent estates for all three compounds have expired or no longer represent a meaningful barrier to generic entry in major jurisdictions.

Active ingredient	Originator product	Patent position	Commercial effect
Zidovudine	Retrovir	Core patents expired	Broad generic availability
Lamivudine	Epivir	Core patents expired	Broad generic availability
Nevirapine	Viramune	Core patents expired	Broad generic availability
Lamivudine/zidovudine	Combivir	Core product protection expired	Generic substitution established

Remaining patents, where present, are more likely to concern specific formulations, manufacturing processes, polymorphs or particular therapeutic uses. These rights generally do not prevent supply of conventional immediate-release tablets in countries where basic compound patents have expired.

What formulations are protected?

Potential formulation claims can cover:

• fixed-dose tablets containing specific ratios;
• low-dose pediatric formulations;
• dispersible or oral-solution products;
• stability-enhanced compositions;
• manufacturing processes that improve dissolution or tablet uniformity.

Formulation patents have limited strategic value for this regimen because multiple generic suppliers can offer conventional tablets using alternative excipients and processes. Public-health procurement also favors low-cost, standard formulations rather than differentiated delivery systems.

When did lamivudine, nevirapine and zidovudine lose exclusivity?

Exclusivity was lost in stages rather than on one common date. Zidovudine entered generic competition earliest. Lamivudine and zidovudine fixed-dose combinations also became available from generic manufacturers after the relevant patent and regulatory barriers expired. Nevirapine followed the same mature-product path.

The commercial result is clear:

1. Branded price premiums declined.
2. Generic suppliers entered through national registrations and international procurement.
3. Public buyers shifted toward fixed-dose combinations.
4. Newer regimens reduced clinical demand for the three-drug combination.

No current exclusivity period is expected to support a premium-priced global product based solely on lamivudine, nevirapine and zidovudine.

How strong is the patent estate for the combination?

The patent estate is weak from a market-exclusion perspective.

Patent category	Strength	Impact on generic entry
Core compound patents	Low	Expired or commercially ineffective
Basic tablet formulation	Low	Easily substituted by alternative formulations
Fixed-dose combination claims	Low to moderate	May affect specific products, not the whole market
Pediatric formulations	Moderate in limited jurisdictions	Narrow commercial scope
Manufacturing patents	Low to moderate	Can be designed around
Method-of-use patents	Low	Limited relevance where treatment guidelines have changed

A supplier may hold enforceable rights in a particular country, especially for a specific formulation or process. Those rights do not create a durable global moat.

Are there Paragraph IV challenges or major patent litigation?

There is no major current U.S. Paragraph IV litigation landscape centered on a branded lamivudine-nevirapine-zidovudine triple product. The relevant patent disputes occurred during the earlier antiretroviral market, when originators defended compound and combination patents against generic manufacturers.

The present risk is regulatory and commercial rather than litigation-driven. A generic supplier typically faces:

• product registration requirements;
• bioequivalence or comparative dissolution requirements;
• procurement qualification;
• manufacturing inspection;
• pharmacovigilance obligations;
• country-specific intellectual-property review.

For a mature conventional tablet, patent litigation is unlikely to be the principal barrier to entry.

What is the competitive landscape for the regimen?

The principal competition comes from newer antiretroviral combinations rather than from another three-drug product containing the same ingredients.

Competing regimen	Market position	Effect on NVP/ZDV/3TC
Dolutegravir plus lamivudine and tenofovir	Preferred public-health regimen in many markets	Major substitution threat
Tenofovir/lamivudine/dolutegravir	Widely adopted first-line regimen	Directly displaces zidovudine and nevirapine
Efavirenz-based regimens	Older low-cost alternative	Competes in price-sensitive markets
Atazanavir- or darunavir-based therapy	Used in selected treatment settings	Limited direct substitution
Pediatric dolutegravir formulations	Growing role in children	Reduces demand for nevirapine-based pediatric therapy

WHO guidelines recommend dolutegravir-based regimens for most adults, adolescents and children, subject to clinical circumstances and local implementation (World Health Organization, 2021, 2023). This change has weakened demand for nevirapine-containing therapy.

What is the market size and financial trajectory?

There is no reliable standalone global revenue figure for the exact three-drug combination. Manufacturers and procurement agencies generally report antiretroviral sales by product, country or program, while the three active ingredients are also sold in separate combinations.

The financial trajectory is nevertheless identifiable:

Period	Market condition	Financial direction
1990s	Branded antiretroviral expansion	High price and strong originator economics
2000s	Generic entry and donor procurement	Rapid price compression
2010s	Fixed-dose generic scale-up	Volume growth, margin decline
2020s	Dolutegravir-led treatment migration	Structural volume decline for NVP/ZDV/3TC
Forward outlook	Residual use in selected markets	Low growth, low margin, procurement-dependent

Revenue exposure is concentrated in generic manufacturers that sell through national HIV programs, Global Fund-supported tenders, PEPFAR-linked procurement and other public-health channels. Commercial returns depend on manufacturing scale, registration coverage and tender wins rather than brand equity.

The combination can remain financially viable where:

• treatment guidelines have not fully transitioned;
• procurement budgets prioritize the lowest unit price;
• legacy patients remain stable on therapy;
• pediatric or prevention protocols retain a role for zidovudine or nevirapine;
• local manufacturers receive preference in public tenders.

The long-term outlook is negative because the product lacks differentiation and competes against more effective, better tolerated and simpler regimens.

Which companies supply or compete in this market?

Generic supply has historically included Cipla, Hetero, Mylan or Viatris, Aurobindo and other regional manufacturers, depending on country registration and procurement eligibility. Originator companies remain relevant primarily through legacy products, intellectual property history and portfolio transitions rather than current growth.

Cipla has been particularly visible in affordable antiretroviral treatment and fixed-dose combinations. Viatris and Aurobindo have participated in generic HIV supply across multiple markets. Supplier rankings vary by tender cycle, country and donor purchasing mechanism.

Licensing arrangements have historically supported generic HIV access through mechanisms such as voluntary licenses, Medicines Patent Pool agreements and donor-backed procurement. Current commercial value is more closely linked to supply contracts and quality accreditation than to licensing royalties for this mature combination.

What generic launch risks exist?

A new generic launch faces low patent risk but meaningful execution risk.

Regulatory risk

The applicant must demonstrate compliance with local quality standards and, where applicable, bioequivalence requirements. WHO prequalification or stringent-regulatory-authority approval can improve access to international procurement programs.

Manufacturing risk

The three active ingredients have different stability, assay and dissolution characteristics. A manufacturer must control:

• content uniformity;
• degradation products;
• tablet stability;
• packaging under heat and humidity;
• supply continuity for all three APIs.

Commercial risk

Tender prices can be compressed by several qualified suppliers. A product may obtain approval but fail to generate material revenue if it lacks donor-program eligibility, local registration or reliable API sourcing.

Clinical risk

Nevirapine has clinically important hypersensitivity and hepatotoxicity concerns. Zidovudine is associated with anemia, neutropenia and mitochondrial toxicity. These risks reduce physician preference and increase the probability of substitution by newer regimens.

How does this regimen compare with dolutegravir-based therapy?

Attribute	NVP/ZDV/3TC	Dolutegravir-based regimen
Pill burden	Usually higher or less convenient	Often once daily with a simple fixed-dose tablet
Tolerability	Less favorable	Generally more favorable
Resistance barrier	Lower	Higher
Current guideline status	Mostly legacy or alternative use	Preferred in many settings
Patent position	Mature generic	Some markets retain formulation or product patents
Price	Very low	Also declining through generic competition
Growth outlook	Declining	Expanding or stable

Dolutegravir-based products have reduced the addressable market for nevirapine- and zidovudine-containing regimens even where the older combination remains cheaper.

What is the outlook for biosimilar risk?

Biosimilar risk is not relevant. Lamivudine, nevirapine and zidovudine are small-molecule drugs, not biologics. The relevant competitive threat is generic substitution, not biosimilar entry.

What geographic markets remain relevant?

The remaining market is concentrated in countries where HIV treatment programs still use older regimens for cost, supply or patient-specific reasons. Demand is more likely to persist in parts of sub-Saharan Africa, South Asia and other lower- and middle-income markets than in the United States, Western Europe or Japan.

Geographic opportunity depends on:

• national HIV treatment guidelines;
• donor procurement policies;
• local registration;
• tender participation;
• supplier qualification;
• treatment migration to dolutegravir.

The product has little potential for premium expansion in regulated high-income markets.

Key Takeaways

• Lamivudine-nevirapine-zidovudine is a mature generic HIV regimen, not a high-growth branded product.
• The core patent barriers for all three compounds have expired or lost practical market significance.
• No major current Paragraph IV or U.S. litigation risk defines the market.
• FDA treatment practice and WHO guidance have shifted toward dolutegravir-based therapy.
• Product-level revenue is not reported reliably because the ingredients are sold separately and in multiple combinations.
• Financial performance depends on public procurement, donor programs, registration coverage and manufacturing cost.
• The market outlook is declining in volume and structurally low-margin.
• Generic-entry risk is primarily commercial and regulatory, not patent-based.
• Biosimilar competition is irrelevant because the products are small molecules.
• The strongest remaining commercial position is low-cost supply into selected public-health and legacy-treatment markets.

FAQs

Is there an FDA-approved triple tablet containing lamivudine, nevirapine and zidovudine?

There is no major U.S. branded triple product comparable to Combivir. The three ingredients have been used together in generic and country-specific fixed-dose products, but U.S. commercial availability has been limited.

Is Combivir the same as lamivudine-nevirapine-zidovudine?

No. Combivir contains lamivudine and zidovudine only. It does not contain nevirapine.

Can generic manufacturers still launch this combination?

Yes. The principal barriers are country registration, quality compliance, procurement qualification and price competition. Core patent protection is not the main obstacle.

Why has nevirapine use declined?

Nevirapine has a lower resistance barrier and important hypersensitivity and hepatotoxicity risks. Dolutegravir-based regimens offer better efficacy, tolerability and resistance characteristics in most treatment settings.

Does this combination have meaningful licensing value?

Its licensing value is limited. Any commercial value is more likely to arise from supply agreements, public tenders, local manufacturing rights or procurement qualification than from royalty-bearing exclusivity.

References

1. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (1997). Combivir approval history and prescribing information. U.S. Department of Health and Human Services.

3. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.

4. World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. WHO.

5. World Health Organization. (2023). The WHO consolidated guidelines on tuberculosis, module 4: Treatment - drug-resistant tuberculosis treatment. WHO.

6. World Health Organization. (2024). WHO prequalification of medicines programme: HIV medicines. WHO.